GH Research PLC $GHRS Stock: Jefferies Financial Group Inc. Trims Position

Jefferies Financial Group Inc. cut its position in shares of GH Research PLC (NASDAQ:GHRS) by 49.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 362,361 shares of the company’s stock after selling 349,939 shares during the period. Jefferies Financial Group Inc. owned about 0.53% of GH Research worth $8,508,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in GHRS. Troluce Capital Advisors LLC grew its position in shares of GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after buying an additional 617,260 shares in the last quarter. Braidwell LP purchased a new position in shares of GH Research during the second quarter valued at $5,571,000. Renaissance Technologies LLC bought a new stake in shares of GH Research in the first quarter valued at about $290,000. Squarepoint Ops LLC bought a new stake in shares of GH Research in the second quarter valued at about $495,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of GH Research by 9,720.0% in the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock valued at $231,000 after acquiring an additional 9,720 shares in the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Trading Down 1.6%

Shares of NASDAQ GHRS opened at $19.25 on Thursday. GH Research PLC has a 12-month low of $12.04 and a 12-month high of $31.44. The stock’s fifty day simple moving average is $22.67 and its two-hundred day simple moving average is $21.62. The stock has a market capitalization of $1.32 billion, a PE ratio of -19.25 and a beta of 1.31.

Wall Street Analyst Weigh In

GHRS has been the subject of a number of research reports. Guggenheim upped their price objective on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 target price on the stock. New Street Research set a $65.00 price target on shares of GH Research in a report on Monday, August 10th. Finally, Cantor Fitzgerald boosted their price target on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, GH Research currently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.